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Objectives: Chronic obstructive pulmonary disease (COPD) is prevalent among 
adults in China and widespread among smokers. This study assessed health out-
comes of COPD-diagnosed smokers vs. never smokers in urban China. MethOds: 
National Health and Wellness Survey (NHWS) 2010 and 2012 China data were ana-
lyzed. NHWS is a mixed-methodology, Internet-based, nationwide survey of adults 
(18+ years) stratified by gender and age to represent the demographic composition 
of urban China. Respondents self-reporting diagnosis with COPD were categorized 
as smoking (including [non]smokers in process of quitting) or never having smoked. 
Respondents reported on health status: SF-36v2-based Mental (MCS) and Physical 
(PCS) Component Summary scores and SF-6D health utilities; productivity loss: 
Work Productivity and Activity Impairment questionnaire-based metrics; and 
resource utilization in the past six months. Regression modeling assessed health 
outcomes as a function of smoking, controlling for demographics, time since diag-
nosis, and comorbidities. Results: Among 1,421 diagnosed with COPD, 51.6% never 
smoked and 35.5% smoked (of whom, 43.8% were attempting to quit). Smokers vs. 
never smokers were more likely to be male (82.4% vs. 36.4%, respectively), recently 
diagnosed with COPD (i.e., 8.56 vs. 11.09 years), employed, wealthier, partnered, 
overweight, and with higher comorbid risk (all p< 0.05). Adjusting for covariates, 
smokers vs. never smokers had lower health utilities (-0.022 points, p< .001), PCS 
(-1.26 points, p= .043), and MCS (-2.85 points, p< .001), and higher rates of absentee-
ism (44.7% greater, p= .002), impairment while working (22.4%, p< .001), overall work 
impairment (22.3%, p< .001), activity impairment (16.5%, p= .002), emergency room 
visits (65.6%, p< .001), hospitalizations (142.9%, p< .001), and provider visits (23.0%, 
p= .038). On average, impairments were greater and more consistently significant 
among females. cOnclusiOns: Even after adjusting for significant baseline dif-
ferences, smokers vs. never smokers with COPD in urban China experienced poorer 
health outcomes, suggesting the importance of secondary prevention of COPD in 
this population, as well as smoking cessation interventions.
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Objectives: The Huntington Quality of Life Instrument (H-QoL-I) is a self-
administered instrument developed specifically to measure the quality of life of 
patients affected by the Huntington’s disease (HD). It was originally developed 
and validated for France and Italy. This study aimed to validate the US version of 
H-QoL-I. MethOds: The H-QoL-I was composed of 11 items organized into 3 dimen-
sions: motor functioning (4), psychology (4) and socializing (3). Item response can be 
chosen among 5 possibilities, depending on frequency or intensity. The instrument 
was translated forwards and backwards by native speakers. A survey was conducted 
with 170 patients. Internal validity was tested, assessing internal consistency, cor-
relation matrix using item/dimension correlation and factorial structure. External 
validation, using Pearson’s correlation, was performed versus clinical dimension 
scores (motor, functional, temper, depression/anxiety), and the EuroQoL 5D (EQ-
5D). Results: The mean (± standard deviation) age of patients was 49 (±14) years 
and 68% were female. The H-QoL-I showed a good reliability despite the item reduc-
tion (Cronbach’s alpha coefficients were higher than 0.8 for the 3 dimensions). 
Factor analysis explained 79% of the total variance and demonstrated the same 
structure as the French and Italian version. Internal consistency was satisfactory 
for all dimensions, ranging from 0.62 to 0.90. The correlation of each item with its 
associated dimension was higher than its correlation with the other dimensions 
(item discriminate validity). The external validity supported the anticipated cor-
relations between each dimension and the clinical and functional dimensions of 
the Huntington Clinical Self-Reported Instrument (H-CSRI) and the EQ-5D index 
score. The correlation between total H-QoL-I score and EQ-5D index score was 
0.76. cOnclusiOns: The H-QoL-I, which has sound psychometric properties, is a 
valid instrument for measuring the disease specific Health Related Quality of Life 
(HRQoL) of patients with HD in the US.
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Objectives: Huntington’s disease (HD) is a chronic degenerative disorder that 
causes movement abnormalities, cognitive deterioration and affective disturbances. 
The Huntington Clinical Self-Reported Instrument (H-CSRI) is the first clinimet-
ric patient assessed scale for patients with HD. It was originally developed and 
validated for France and Italy and then for Spain. The objective of this study is to 
adapt and validate the H-CSRI for US. MethOds: The H-CSRI, previously validated 
questionnaire, included three subscales assessing: the motor (13 five point Likert-
type items in 4 dimensions), functional (7 Yes/No questions) and behavioural ability 
(13 five point Likert type items in 4 dimensions). It was translated forwards and 
backwards by native speakers and then reviewed by local clinicians and adjusted as 
required. 170 patients completed the questionnaire. While face validity was studied 
PRS50
effeCTiveneSS of TexT meSSAge ReminDeRS in ASThmA meDiCATion 
ADheRenCe: A SySTemATiC RevieW
Ali A.A., Xiao H., Adunlin G.
Florida A&M University, Tallahassee, FL, USA
Objectives: Cell phone text messaging reminders, via the Short Messaging Service 
(SMS), offers the promise of an efficient technology for the management of chronic 
diseases, such as asthma. This review aims to evaluate the effectiveness of text mes-
sage reminders on adherence to asthma medication by comparing adherence among 
individuals who received text message medication reminders and those who did 
not. MethOds: A systematic review of the literature was conducted to identify pub-
lished studies. Literature search was restricted to English language and no restrictions 
were imposed on the year and country of publication. Medication adherence was 
the primary measure of intervention in eligible studies. Eligible studies had to have 
a control group, and had to assess the impact of text message reminders on medica-
tion adherence. Results: Of the 64 retrieved articles, 4 fulfilled the inclusion criteria. 
Three of these studies were randomized control trials and one was a non-randomized 
control trial. Three of the studies found text message reminders improved medication 
adherence among individuals who received them when compared to those who did 
not. cOnclusiOns: This review adds to the body of literature reviewing the effective-
ness of widely available and instant technologies in the management of disease. Our 
findings suggest that text message reminders can help improve medication adher-
ence among individuals with asthma. Future studies are needed to strengthen the 
evidence on the effectiveness of text message reminders, patient accessibility to this 
technology, and its acceptance by health care providers.
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Objectives: To evaluate patient-reported treatment adherence in patients with 
asthma between two classes of asthma treatments, inhaled corticosteroids (IC) and 
leukotriene modifiers (LM). MethOds: Participants were identified via MediGuard, 
a novel digital patient platform where patients enroll online via the internet to be 
part of a digital patient community. All information was obtained through partici-
pant self-report. Between 2011 through 2013, MediGuard members with asthma 
were invited to complete the Medication Adherence Report Scale (MARS), a patient 
reported outcome (PRO) instrument that measures aspects of medication adherence. 
MARS scores for high versus low adherence (i.e., scores ≥ 20 out of 25 indicate high 
adherence) were compared between the IC and LM groups using logistic regres-
sion analyses, adjusting for demographic variables, disease severity and number 
of concomitant medications. Results: A total of 365 (IC) and 164 (LM) patients 
participated. Age was similar between groups (mean [SD] = 58.7 [13.3] years vs. 
57.7 [10.7] for IC and LM, respectively); and both groups were predominantly female 
(73.8% for IC; 79.0% for LM). Disease severity and number of concomitant medica-
tions taken were similar between IC and LM groups. Ninety-two percent (n= 151) 
of the LM group had high levels of adherence according to the MARS versus 73% 
(n= 265) of the IC group. In multivariable analyses, patients taking LM had 4.6 (95% 
CIs: 2.5-8.5) times the odds of having high adherence to treatment versus patients 
taking IC. cOnclusiOns: These results suggest higher adherence with oral ver-
sus inhaled agents in asthma after controlling for potential confounders. Further 
exploration regarding why adherence differs between these classes is warranted. 
In addition, investigations into how adherence may be enhanced and the impact of 
low adherence on treatment effectiveness should be performed. Providing patients 
with information on adherence could help inform patients’ treatment decisions.
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Objectives: This post-hoc analysis examined the relationship between the 
EQ-5D index and the visual analog scale (VAS), and pulmonary function measured 
using percent predicted forced expiratory volume in 1 second (FEV1), in patients 
with cystic fibrosis (CF) participating in the STRIVE clinical trial. MethOds: In a 
48-week randomized, placebo-controlled study of ivacaftor in patients aged ≥ 12 
years with CF and a G551D-CFTR mutation, the EQ-5D (index and VAS) and FEV1 
were measured directly from patients at baseline, 15 days, 8 weeks, and every 8 
weeks thereafter. The EQ-5D index was calculated using the U.S. preference-based 
algorithm. Pooling assessments and treatments over time, measures were com-
pared among patients with no (FEV1≥ 90%), mild (70-< 90%), moderate (40-< 70%), 
and severe (< 40%) lung dysfunction. Ceiling effects (EQ-5D index= 1 or VAS= 100) 
were also assessed. Results: 121 patients contributed 1214 observations (FEV1: 
157 no lung dysfunction, 419 mild, 572 moderate, 66 severe). Mean index/VAS scores 
decreased with worsening lung function (no lung dysfunction: 0.967/90.0; mild: 
0.949/84.5; moderate: 0.918/75.1; severe: 0.881/66.4). The EQ-5D index and VAS were 
at the ceiling in 67.5% (no lung dysfunction: 80.9%; mild: 73.3%; moderate: 62.1%; 
severe: 45.5%) and 5.6% (no lung dysfunction: 15.9%; mild: 6.9%; moderate: 2.4%; 
severe: 0.0%) of observations, respectively. cOnclusiOns: In a clinical study of 
patients 12 years of age and older with CF and a G551D-CFTR mutation, the EQ-5D 
index and VAS demonstrated monotonic decreases with decreasing FEV1. The EQ-5D 
VAS was more discriminating of CF lung disease severity than the index score. 
Ceiling effects were high, particularly for the EQ-5D index and for patients with no 
lung dysfunction or mildly affected lung function. Both instruments provide com-
plementary health status information; however, the use of the EQ-5D index alone 
may limit characterization of disease burden and health gains in cost-effectiveness 
analyses of CF therapies.
